Antibiotics Improve Survival in Severe Malnutrition
Oral antibiotics amoxicillin and cefdinir show efficacy in a randomized study of children with severe acute malnutrition. Linda MacArthur, PhD February 14, 2013—In children with severe acute malnutrition, a one week course of amoxicillin or cefdinir, combined with ready-to-use therapeutic food (RUTF), improved nutritional recovery and reduced mortality compared with placebo, according to the findings of a double-blind, randomized trial conducted in Malawi. Mark Manary, MD, with Washington University in St. Louis, Missouri, and colleagues reported their findings in the January 31, 2013 issue of The New England Journal of Medicine. According to the researchers, the use of routine antibiotics for treatment of outpatient malnutrition is based on observational data but this practice has not been tested in clinical trials. The current trial was designed to determine the effect of antibiotic use on nutritional recovery and mortality rates, as compared with placebo. A total of 2767 children ages 6-59 months of age in rural Malawi with edema and a weight-for-height z score of less than -3 were randomized to receive RUTF (175 kcal/kg body weight/day) and 1 week of amoxicillin suspension (80-90 mg /kg/day divided into 2 doses, N=924), cefdinir suspension (14 mg/kg/day divided into 2 doses, N=923), or placebo (N=920). RUTF continued for the duration of the study for 6 biweekly follow-up visits. The primary outcome measures were nutritional recovery, as defined by the absence of edema and weight-for-height z scores of -2 or higher, and mortality rates. Overall, the percent of children that did not recover was significantly higher in the placebo group compared with the groups receiving amoxicillin or cefdinir (14.9% vs. 11.3 and 9.1; P =0.02 for placebo vs. amoxicillin and P<0.001 for placebo vs. cefdinir). Amoxicillin and cefdinir significantly reduced mortality rates compared with placebo (4.8% and 4.1% vs. 7.4%; P =0.02 for placebo vs. amoxicillin and P =0.003 for placebo vs. cefdinir). Children with marasmic kwashiorkor had lower rates of nutritional recovery and higher mortality than children with either kwashiorkor or marasmus. Fewer children failed to recover with antibiotics (30.8% for amoxicillin and 30.1% for cefdinir compared with 40.9% for placebo) but the results did not reach statistical significance. Overall nutritional recovery rates were higher and death rates were lower among children that received cefdinir than those that received amoxicillin, although these differences were not statistically significant (P=0.22 for recovery and P=0.53 for death). Treatment failure was significantly associated with younger age (P=0.02), marasmic kwashiorkor (P=0.002), HIV exposure or infection, and greater growth stunting (P<0.001), and these factors were significantly correlated with increased risk of death (P=0.01 for younger age and P<0.001 for others). Good appetite upon enrollment correlated with reduced risk of death (P=0.001).
Adverse effects for amoxicillin included a generalized papular rash in one child. One child that received cefdinir developed thrush and another developed bloody diarrhea that resolved spontaneously. There was no reported severe allergy or anaphylaxis. According to the researchers, their results suggest that “children with uncomplicated severe acute malnutrition who qualify for outpatient therapy remain at risk for severe bacterial infection and that the routine inclusion of antibiotics as part of their nutritional therapy is warranted.” This study was funded by the Hickey Family Foundation, the Academy for Educational Development and grants for statistical consulting from NIH.
Occurrence of antibiotic resistant bacteria in waste site of Ede south west NigeriaInstitute of Ecology and Environmental Studies, Obafemi Awolowo University, Ile-Ife, Nigeria(Received: June 19, 2007; Revised received: November 30, 2007; Accepted: December 05, 2007)Abstract: Analysis of antibiotic resistant bacteria from composted waste site soil samples for two seasons were done, using prepare
Efavirenz Marca comercial: Clase de medicamento: Inhibidor de la transcriptasa inversa no análogo El efavirenz, conocido también como EFV o Sustiva, es un tipo de antirretroviral llamado inhibidor de latranscriptasa inversa no análogo de los nucleósidos (NNRTI). Esta clase de medicamentos bloquea latranscriptasa inversa, una proteína que necesita el VIH para multiplicarse.